Site-specific propynylation modification of apigeninidin enhances anti-cervical cancer activity by targeting PARP-1

Key Points

• Anti-cervical cancer activity is significantly enhanced through propynylation modification of apigeninidin, targeting PARP-1.
• Measurements show that propynylated apigeninidin exhibits increased binding affinity to PARP-1, facilitating cancer cell death.
• Analysis on cervical cancer models reveals that the site-specific modification leads to substantial improvements in therapeutic efficacy.
• These findings may enable the development of more effective cancer treatments centered on molecular modification strategies.